GERMANY - Ganymed increases series-C financing

The additional capital was fully subscribed by ATS Beteiligungsverwaltung GmbH, Munich, who already participated in the first closing. At the same time, the company announced the election of Hans-Beat Gürtler as a new member of the Supervisory Board. Gürtler replaces Dr Harald Poth, who will continue to represent LBBW as observer to the Supervisory Board.

Ganymed is a biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers. The company is building a growing sustainable pipeline of antibody therapeutics targeting solid cancers with high medical need and large market potential.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH